FDA approves once-monthly subcutaneous amivantamab dosing in EGFR-mutated NSCLC
The FDA approved once-monthly subcutaneous amivantamab with lazertinib for first-line EGFR-mutated advanced NSCLC. PALOMA-2 showed high response rates and no new safety signals.